Educational Sessions: "CDK4/6 for ER+"

Education Session: Treatment Post CDK 4/6 InhibitorsПодробнее

Education Session: Treatment Post CDK 4/6 Inhibitors

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical UseПодробнее

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use

CDK4/6 Inhibitors Making the Difference ” Dr. Ahmed SaadeddinПодробнее

CDK4/6 Inhibitors Making the Difference ” Dr. Ahmed Saadeddin

Expert Perspectives: CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast CancerПодробнее

Expert Perspectives: CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast CancersПодробнее

The Truth About CDK4/6 Inhibitors – New Targeted Treatment Protocol for ER Positive Breast Cancers

Expert Perspectives: Targeting Advanced ER+ Metastatic Breast Cancer with CDK 4/6 InhibitorsПодробнее

Expert Perspectives: Targeting Advanced ER+ Metastatic Breast Cancer with CDK 4/6 Inhibitors

The Biological Rationale for CDK4/6 InhibitorsПодробнее

The Biological Rationale for CDK4/6 Inhibitors

Educational Sessions: "CDK4/6 for ER+"Подробнее

Educational Sessions: 'CDK4/6 for ER+'

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNA

CDK 4/6 Inhibitors: How are they used in metastatic breast cancer treatment?Подробнее

CDK 4/6 Inhibitors: How are they used in metastatic breast cancer treatment?

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

Survival analysis of of CDK4/6 inhibitors andendocrine therapy in HR positive,her2 negative Day1Подробнее

Survival analysis of of CDK4/6 inhibitors andendocrine therapy in HR positive,her2 negative Day1

Treatment of disease progression after first line cdk4/6 inhibitors By Dr. Omalkhair AbulkhairПодробнее

Treatment of disease progression after first line cdk4/6 inhibitors By Dr. Omalkhair Abulkhair

Emerging evidence on the role of CDK4/6 inhibitors in early BCПодробнее

Emerging evidence on the role of CDK4/6 inhibitors in early BC

Ongoing Investigations and Future Applications of CDK 4/6 InhibitorsПодробнее

Ongoing Investigations and Future Applications of CDK 4/6 Inhibitors

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future ImplicationsПодробнее

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future Implications

Current and future CDK4/6 inhibitors in high-risk early-stage HR+ breast cancerПодробнее

Current and future CDK4/6 inhibitors in high-risk early-stage HR+ breast cancer

Mechanistic Activity and Development History of CDK 4/6 InhibitorsПодробнее

Mechanistic Activity and Development History of CDK 4/6 Inhibitors

Current Clinical Data for CDK 4/6 Inhibitors in Breast CancerПодробнее

Current Clinical Data for CDK 4/6 Inhibitors in Breast Cancer